Advertisement

Topics

Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy

07:09 EST 1 Dec 2017 | FinanzNachrichten

Stock Monitor: Cleveland BioLabs Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Capricor Therapeutics, Inc. (NASDAQ: CAPR), which is ...

Original Article: Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy

NEXT ARTICLE

More From BioPortfolio on "Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy"

Advertisement
Quick Search
Advertisement
Advertisement